

amended, notice is hereby given of a meeting of the National Advisory Council on Aging.

The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Advisory Council on Aging.

*Date:* September 15–16, 2026.

*Closed:* September 15, 2026, 12:30 p.m. to 2:30 p.m.

*Agenda:* To review and evaluate grant applications.

*Address:* National Institutes of Health, Natcher Building, 45 Center Drive, Bethesda, MD 20892 (In Person and Virtual Meeting).

*Open:* September 16, 2026, 9:00 a.m. to 1:00 p.m.

*Agenda:* Director Status Report; Staff Introductions, Council Business.

*Address:* National Institutes of Health, Natcher Building, 45 Center Drive, Bethesda, MD 20892 (In Person and Virtual Meeting).

*Contact Person:* Kenneth Santora, Director, Office of Extramural Activities, National Institute on Aging, National Institutes of Health, Gateway Building, 7201 Wisconsin Avenue, Bethesda, MD 20814, (301) 496–9322, [ksantora@nih.gov](mailto:ksantora@nih.gov).

In the interest of security, NIH has procedures at <https://security.nih.gov/visitors/Pages/visitor-campus-access.aspx> for entrance into on-campus and off-campus facilities. All visitor vehicles, including taxicabs, hotel, and airport shuttles will be inspected before being allowed on campus. Visitors attending a meeting on campus or at an off-campus federal facility will be asked to show one form of identification (for example, a government-issued photo ID, driver's license, or passport) and to state the purpose of their visit.

Information is also available on the Institute's/Center's home page: [www.nia.nih.gov/about/naca](http://www.nia.nih.gov/about/naca), where an agenda and any additional information for the meeting will be posted when available. (Catalogue of Federal Domestic Assistance Program Nos. 93.866, Aging Research, National Institutes of Health, HHS)

Dated: November 17, 2025.

**Margaret Vardanian,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2025–20315 Filed 11–18–25; 8:45 am]

**BILLING CODE 4140–01–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Meeting

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the National Diabetes and Digestive and Kidney Diseases Advisory Council.

The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Diabetes and Digestive and Kidney Diseases Advisory Council.

*Date:* May 13, 2026.

*Open:* May 13, 2026, 8:30 a.m. to 12:00 p.m.

*Agenda:* Council Business.

*Open:* May 13, 2026, 1:00 p.m. to 2:30 p.m.

*Agenda:* KUH Open session.

*Open:* May 13, 2026, 1:00 p.m. to 2:30 p.m.

*Agenda:* DEM Open session.

*Open:* May 13, 2026, 1:00 p.m. to 2:30 p.m.

*Agenda:* DDN Open session.

*Closed:* May 13, 2026, 2:30 p.m. to 3:30 p.m.

*Agenda:* To review and evaluate grant applications.

*Closed:* May 13, 2026, 2:30 p.m. to 3:30 p.m.

*Agenda:* To review and evaluate grant applications.

*Closed:* May 13, 2026, 2:30 p.m. to 3:30 p.m.

*Agenda:* To review and evaluate grant applications.

*Closed:* May 13, 2026, 3:45 p.m. to 4:00 p.m.

*Agenda:* Reports of Subcommittees and Consideration of Applications.

*Address:* National Institutes of Health, Building 31, C Wing 6th Floor Conf. Room F&G, 31 Center Drive, Bethesda, MD 20892 (In Person and Virtual Meeting).

*Contact Person:* Karl F. Malik, Ph.D., Director, Division of Extramural Activities, National Institutes of Diabetes and Digestive and Kidney Diseases, 6707 Democracy Blvd., Room 7329, MSC 5452, Bethesda, MD 20892, (301) 594–4757, [malikk@nidk.nih.gov](mailto:malikk@nidk.nih.gov).

In the interest of security, NIH has procedures at <https://security.nih.gov/visitors/Pages/visitor-campus-access.aspx> for entrance into on-campus and off-campus facilities. All visitor vehicles, including taxicabs, hotel, and airport shuttles will be inspected before being allowed on campus. Visitors attending a meeting on campus or at an off-campus federal facility will be asked to show one form of identification (for example, a government-issued photo ID, driver's license, or passport) and to state the purpose of their visit.

Information is also available on the Institute's/Center's home page: <https://www.nidk.nih.gov/about-nidk/advisory-coordinating-committees/national-diabetes-digestive-kidney-diseases-advisory-council>, where an agenda and any additional information for the meeting will be posted when available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.847, Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive Diseases and Nutrition Research; 93.849, Kidney Diseases, Urology and Hematology Research, National Institutes of Health, HHS)

Dated: November 17, 2025.

**Margaret Vardanian,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2025–20316 Filed 11–18–25; 8:45 am]

**BILLING CODE 4140–01–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Prospective Grant of an Exclusive Patent License: Methods for the Diagnosis and Prognosis of Cancer

**AGENCY:** National Institutes of Health, HHS.

**ACTION:** Notice.

**SUMMARY:** The National Cancer Institute and the National Institute of Arthritis and Musculoskeletal and Skin Diseases, institutes of the National Institutes of Health, Department of Health and Human Services, are contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the patent applications listed in the **SUPPLEMENTARY INFORMATION** section of this notice to BioncoDx, LLC, a company organized in Delaware.

**DATES:** Only written comments and/or applications for a license which are received by the National Cancer Institute's Technology Transfer Center on or before December 4, 2025 will be considered.

**ADDRESSES:** Requests for copies of the patent application, inquiries, and comments relating to the contemplated an Exclusive Patent License should be directed to: Todd Testerman, Ph.D., Technology Transfer Manager, NCI Technology Transfer Center, Telephone: 240-620-0822; Email: [todd.testerman@nih.gov](mailto:todd.testerman@nih.gov).

**SUPPLEMENTARY INFORMATION:**

**Intellectual Property**

1. US Provisional Patent Application No. 61/845,055 filed July 11, 2013, and entitled "Method for the Diagnosis And Prognosis of Cancer" [HHS Reference No. E-121-2013-0-US-01];

2. International PCT Application No. PCT/US2014/046294 filed July 11, 2014, and entitled "Method for the Diagnosis And Prognosis of Cancer" [HHS Reference No. E-121-2013-0-PCT-02];

3. US Patent No. 10,393,745 issued 8/27/2019, and entitled "Method for the Diagnosis And Prognosis of Cancer" [HHS Reference No. E-121-2013-0-US-04];

4. US Patent No. 11,555,818 issued 1/17/2023, and entitled "Method for the Diagnosis And Prognosis of Cancer" [HHS Reference No. E-121-2013-0-US-05];

5. Europe Patent No. 3019871 issued 10/16/2019, and entitled "Method for the Diagnosis And Prognosis of Cancer" [HHS Reference No. E-121-2013-0-EP-03];

6. German Patent No. 3019871 issued 10/16/2019, and entitled "Method for the Diagnosis And Prognosis of Cancer" [HHS Reference No. E-121-2013-0-DE-06];

7. French Patent No. 3019871 issued 10/16/2019, and entitled "Method for the Diagnosis And Prognosis of Cancer" [HHS Reference No. E-121-2013-0-FR-07]; and

8. United Kingdom Patent No. 3019871 issued 10/16/2019, and entitled "Method for the Diagnosis And Prognosis of Cancer" [HHS Reference No. E-121-2013-0-GB-08].

The patent rights in these inventions have been assigned to the Government of the United States of America.

The prospective exclusive license territory may be worldwide where patent rights exist and the field of use may be limited to the following: "Use of the Patent Rights to develop, manufacture and commercialize a Food and Drug Administration (FDA)

Premarket Approval (PMA)—creatine riboside, metabolite 561+, cortisol sulfate, and N-acetylneuraminic acid metabolite-based prognostic, diagnostic/companion diagnostic, and general screening tests for cancers of the lung/thoracic, breast, colorectal, kidney/bladder, prostate, liver, stomach, pancreatic, GYN (ovary, uterine, cervix) and brain from urine samples." After a negotiated period of time, the exclusive field of use will be reduced to a subset of three cancer indications with strict developmental benchmarks for each indication.

The subject technology is a unique, non-invasive screening tool and diagnostic that can detect cancers, including lung cancer, at an early stage utilizing liquid chromatography-mass spectrometry for the detection of four biomarkers—creatine riboside, metabolite 561+, cortisol sulfate, and N-acetylneuraminic acid—from human clinical samples, particularly urine samples. Urine samples minimize patient discomfort, unlike current early detection methods that are invasive, such as blood or tissue biopsy or bronchoscopy, and can be performed easily during a routine exam.

This Notice is made in accordance with 35 U.S.C. 209 and 37 CFR part 404. The prospective exclusive license will be royalty bearing, and the prospective exclusive license may be granted unless within fifteen (15) days from the date of this published notice, the National Cancer Institute receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR part 404.

Complete applications for a license that are timely filed in response to this notice will be treated as objections to the grant of the contemplated exclusive patent license. In response to this Notice, the public may file comments or objections. Comments and objections, other than those in the form of a license application, will not be treated confidentially, and may be made publicly available.

License applications submitted in response to this Notice will be presumed to contain business confidential information and any release of information in these license applications will be made only as required and upon a request under the Freedom of Information Act, 5 U.S.C. 552.

Dated: November 17, 2025.

**Richard U. Rodriguez,**

*Associate Director, Technology Transfer Center, National Cancer Institute.*

[FR Doc. 2025-20290 Filed 11-18-25; 8:45 am]

**BILLING CODE 4140-01-P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**National Institutes of Health**

**National Institute on Aging; Notice of Meeting**

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the National Advisory Council on Aging.

The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Advisory Council on Aging.

*Date:* January 28–29, 2026.

*Closed:* January 28, 2026, 3:00 p.m. to 5:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Address:* Natcher Building, Building 45, 45 Center Drive, Bethesda, MD 20892 (In Person and Virtual Meeting).

*Open:* January 28, 2026, 10:00 a.m. to 2:00 p.m.

*Agenda:* Call to order and report from the Director; Discussion of future meeting dates; Consideration of minutes of last meeting; Reports from Task Force on Minority Aging Research, Working Group on Program; Council Speaker; Program Highlights.

*Address:* Natcher Building, Building 45, 45 Center Drive, Bethesda, MD 20892 (In Person and Virtual Meeting).

*Closed:* January 29, 2026, 2:00 p.m. to 2:30 p.m.

*Agenda:* To review and evaluate the Intramural Research Program.

*Address:* Natcher Building, Building 45, 45 Center Drive, Bethesda, MD 20892 (In Person and Virtual Meeting).